Celcuity (CELC) is down about 3.36% to $119.42 in Friday trading (April 10, 2026) as the market fades recent biotech momentum and re-focuses on fundamentals following the company’s year-end reporting cycle. The latest company materials in the market’s orbit include Celcuity’s 2025 annual report on Form 10-K and the late-March earnings/corporate update cadence, which reinforced that the company remains in a high-spend, loss-making phase while it pushes toward a potential first approval.

For a clinical-stage oncology company, the near-term trade is increasingly binary: investors are weighing ongoing operating losses and financing needs against the value of a potential near-term FDA approval. Celcuity’s filings reiterate that the FDA accepted its gedatolisib New Drug Application and granted Priority Review, with a PDUFA goal date of July 17, 2026—an unusually clear, dated catalyst that can also increase day-to-day volatility as investors adjust exposure. Today’s pullback appears consistent with de-risking and profit-taking after the earlier regulatory catalyst rather than a single new negative headline.

Celcuity also filed its definitive proxy statement in early April, which outlines items for shareholder vote including equity-plan matters. In small and mid-cap biotech, proxy-season equity plan expansions can amplify dilution sensitivity, particularly when the company is still pre-revenue and funding pivotal trials and launch preparation. That backdrop can contribute to incremental selling pressure on down days even without a discrete news event.

Near-term, attention stays on any FDA review updates ahead of the July 17 decision date and on any signals about commercialization readiness if approved. Traders will also monitor the company’s balance sheet disclosures in recent filings for runway, expected spend, and any hints of future capital raises, since those variables can quickly dominate price action between major clinical or regulatory headlines.